#Shanghai #USA #WuXi Biologics #WuXia293Stable #HEK293

WuXi Biologics Launches Innovative WuXia293Stable Platform

In a significant leap for biopharmaceutical manufacturing, WuXi Biologics has announced the launch of its latest breakthrough, the WuXia293Stable platform, specifically engineered for the development and commercialization of challenging-to-express biomolecules. This pioneering platform utilizes HEK293 cells, renowned for their ability to produce high-yield proteins with exceptional quality, thereby addressing a critical gap in the current biopharmaceutical landscape.

A New Standard in Protein Expression

Traditionally, CHO cells have dominated the field of recombinant protein expression. While these cells have a proven track record for high titers, their efficacy can dwindle when faced with complex modalities. Issues like truncated proteins and low yields often arise due to the influences of CHO host cell proteins (HCPs), which can negatively impact the final product's quality and functionality. In contrast, the HEK293 cell line integrated into WuXia293Stable effectively reduces these truncation issues, ensuring higher yields and better-quality expressions of intricate biomolecules.

With a titration capability of up to 5.0 g/L for monoclonal antibodies, WuXia293Stable not only enhances pureness but also offers flexible scalability suitable for various stages of preclinical research and development. The platform's capacity for stable expression during long-term cell passaging enables scalable clinical and commercial production up to 2000 L for fed-batch processes.

Comprehensive Support and Services

WuXi Biologics is not merely providing a product; it is delivering a full suite of services that include cell bank testing and viral clearance validation. These additions form part of an integrated CMC (Chemistry, Manufacturing, and Controls) solution that ensures client needs are met efficiently.

Dr. Chris Chen, CEO of WuXi Biologics, expressed enthusiasm over this new offering: "We are excited to unveil an industry-leading solution that significantly enhances the development of advanced therapies. WuXia293Stable exemplifies our commitment to innovation in technology and positions us to effectively address the ever-evolving demands in the biopharmaceutical sector. Our ultimate goal is assisting clients in accelerating the delivery of innovative biological products to patients globally."

The Evolution of WuXia™ Platform

The WuXia™ platform is not new in the realm of high-performance mammalian cell lines. This successful program, which has garnered regulatory approvals worldwide, has already generated over 1,000 cell lines for monoclonal antibodies, bispecific antibodies, fusion proteins, and other recombinant proteins for clinical and commercial manufacturing since its inception in 2024.

Complementing the WuXia293Stable platform, the WuXia™ family includes notable platforms such as WuXiaADCC Plus™ for developing afucosylated antibodies and WuXia RidGS™ designed for antibiotic-free cell lines. WuXi Biologics is committed to continuously expanding the WuXia™ suite to meet diverse global customer needs.

In conclusion, the launch of the WuXia293Stable platform not only symbolizes WuXi Biologics' advancement in complex molecule expression but also strengthens the breadth of their service offerings. As the company navigates the complexities of the biopharmaceutical journey, their commitment towards innovative solutions remains steadfast. With WuXia293Stable, WuXi Biologics is now better positioned to tackle the challenges that lie ahead in drug development and therapeutic innovations.